Okogen, Inc., a clinical-stage biotechnology company developing therapies for infectious diseases, announced on October 6, 2026, that the Central Drugs Standard Control Organisation (CDSCO), India's national drug regulatory authority, has authorized the EMERALD study, a Phase 1/2 clinical trial of Treyegen™ (OKG-0303) for acute infectious conjunctivitis. The authorization allows Okogen to advance its lead ophthalmology program into clinical evaluation in India, a country with a high burden of infectious eye disease.
The EMERALD study will enroll more than 300 patients and assess safety, pharmacokinetics, virologic and microbiologic activity, and clinical efficacy. Data from the trial are expected later this year. Treyegen is an investigational ophthalmic therapy that combines ranpirnase, a host-directed antiviral; tobramycin, a broad-spectrum antibacterial; and oxymetazoline, which reduces ocular redness, into a single formulation. Okogen believes this differentiated approach could simplify treatment decisions by providing physicians with a comprehensive option for patients presenting with acute infectious conjunctivitis, regardless of whether the cause is viral or bacterial.
Acute infectious conjunctivitis, commonly known as pink eye, is a highly contagious condition that affects millions worldwide each year. Current treatments often require clinicians to guess whether the infection is viral or bacterial, leading to delayed or inappropriate antibiotic use. A therapy that addresses both forms could reduce unnecessary antibiotic prescriptions, improve patient outcomes, and lower healthcare costs. The EMERALD study is designed to generate the clinical evidence needed to support further development and potential regulatory submissions.
The authorization also represents a milestone for Okogen's broader host-directed antiviral platform built around ranpirnase. The company is advancing ranpirnase-based therapies across four pillars: ophthalmology, medical countermeasures, systemic antivirals, and dermatology. Ophthalmology serves as the lead clinical proving ground, with the goal of applying insights, formulation expertise, and manufacturing capabilities across a wider portfolio of antiviral therapies. For more information, visit www.okogen.com. To view the full announcement, including downloadable images, bios, and more, click here.
For investors and industry observers, the CDSCO authorization signals regulatory confidence in Okogen's approach and could accelerate the company's timeline for bringing a novel conjunctivitis therapy to market. If successful, Treyegen could become the first single-agent treatment for acute infectious conjunctivitis, addressing a significant unmet need and potentially capturing a substantial share of the global ophthalmic anti-infective market. The trial's data readout later this year will be a key catalyst for Okogen and a pivotal moment for the field.
